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Abstract
Background: Treatment outcomes for antiretroviral therapy (ART) patients may vary by gender, but estimates
from current evidence may be confounded by disease stage and adherence. We investigated the gender dif-
ferences in treatment response among HIV-positive patients virally suppressed within 6 months of treatment
initiation.
Methods: We analyzed data from 7,354 patients initiating ART between April 2004 and April 2010 at Themba
Lethu Clinic, a large urban public sector treatment facility in South Africa. We estimated the relations among
gender, mortality, and mean CD4 response in HIV-infected adults virally suppressed within 6 months of
treatment initiation and used inverse probability of treatment weights to correct estimates for loss to follow-up.
Results: Male patients had a 20% greater risk of death at both 24 months and 36 months of follow-up compared to
females. Older patients and those with a low hemoglobin level or low body mass index (BMI) were at increased
risk of mortality throughout follow-up. Men gained fewer CD4 cells after treatment initiation than did women. The
mean differences in CD4 count gains made by women and men between baseline and 12, 24, and 36 months were
28.2 cells/mm3 (95% confidence interval [CI] 22.2–34.3), 60.8 cells/mm3 (95% CI 71.1-50.5 cells/mm3), and 83.0
cells/mm3 (95% CI 97.1-68.8 cells/mm3), respectively. Additionally, patients with a current detectable viral load
( > 400 copies/mL) and older patients had a lower mean CD4 increase at the same time points.
Conclusions: In this initially virally suppressed population, women showed consistently better immune re-
sponse to treatment than did men. Promoting earlier uptake of HIV treatment among men may improve their
immunologic outcomes.
Introduction
The widespread use of highly active antiretroviral ther-apy (HAART) has caused significant reductions in HIV-
related mortality worldwide.1,2 Despite limited resources,
HIV-infected individuals receiving antiretroviral therapy
(ART) in resource-limited settings, including sub-Saharan
Africa, have shown improvements in outcomes comparable to
results from industrialized countries in terms of immunologic
and virologic response.3–9 Even among patients who are ad-
herent to treatment and achieve viral suppression, lack of
immunologic response to ART has been noted to be an im-
portant predictor of subsequent mortality.10–12 As compre-
hensive HIV treatment involving ART is still relatively new in
some resource-limited settings, however, gender differences
in immunologic response to ART among those achieving viral
suppression (< 400 copies/mL) have not been well described.
Differences by gender are critical to understand and address,
particularly in a country like South Africa, which has the
largest number of HIV-infected adults in the world and
where > 20% of women aged 20–24 years were estimated to be
infected with HIV at the end of 2009.13
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Despite the limited information to date, there are reasons to
think that men and women may differ with respect to immune
recovery even if virally suppressed, as treatment outcomes
among those receiving ART (i.e., both suppressed and non-
suppressed patients) have shown differences. Although re-
sults from the developed world are conflicting,14–19 results
from South Africa20 and India21 showed that women had
lower mortality and higher CD4 counts after 1 year on ART. It
is not clear from these studies, however, how much of this
association relates to differences in immunosuppression at
ART initiation, differences in immune recovery over time on
ART, biologic differences by sex, or simply different patterns
of adherence. If women show increased immunologic re-
sponses to ART after achieving viral suppression, this could
explain the reduced mortality women have shown in South
Africa.20 Additionally, high rates of loss to follow-up in some
observational cohorts studied may introduce bias into the
results presented.
Therefore, we set out to address the limitations of earlier
studies by estimating the relations among gender, mortality,
and mean difference in CD4 response at 12, 24, and 36 months
on ART in the Themba Lethu Clinic, Johannesburg, South
Africa, in a population with good mortality data through
matching with the National Vital Registration system and by
using inverse probability of censoring weights to correct es-
timates for loss to follow-up.
Materials and Methods
Cohort description
We conducted a cohort study of patients at the Themba
Lethu Clinic. Themba Lethu is one of the largest ART clinics in
South Africa, with nearly 32,000 patients enrolled in care since
the clinic’s inception in April 2004. Over 21,000 of these pa-
tients have been initiated on ART. Care was provided by clinic
staff during the study period according to the 2004 South
African National Department of Health guidelines.22 Use of
data for this analysis was approved by the Human Research
Ethics Committee of the University of the Witwatersrand.
Approval for analysis of de-identified data was granted by the
Institutional Review Board of Boston University.
Study population
Our analysis included nonpregnant, ART-naı̈ve, HIV-
positive patients > 18 years of age, initiated onto standard
public sector first-line ART regimens between April 2004 and
April 2010. Pubic sector regimens include stavudine (d4T) or
zidovudine (AZT) with lamivudine (3TC) and either efavirenz
(EFV) or nevirapine (NVP). Patients with a baseline (within 6
months before ART initiation) CD4 count < 350 cells/mm3
who suppressed their HIV viral load by 6 months on treatment
were included in the analysis. Pregnant women were ex-
cluded, as they are initiated on different ART regimens and
have more variable CD4 counts than the general treated
population because of the hemodilution effect of pregnancy.23
Study variables
Patient-level data at Themba Lethu are captured in an
electronic patient management system (Therapy Edge-
HIVTM). The primary exposure was patient gender. Baseline
characteristics were stratified by gender and summarized
with descriptive statistics. The primary dependent variables
were mortality and mean change in CD4 cell count from
baseline to 12, 24, and 36 months of treatment. Deaths are
ascertained by either hospital notification, families notifying
clinic staff, counselors identifying deaths through active
tracing, or linkage with the South African National Vital Re-
gistration Infrastructure Initiative.24–26 Loss to follow-up was
defined as having not attended a scheduled clinic visit within
4 months. For death, person-time accrued from ART initiation
until the earliest of (1) death, (2) loss to follow-up, or (3) close
of the dataset (March 31, 2011) was used. Transferred patients
were censored at their last visit.
Statistical analysis
Clinical and demographic characteristics of the patients
included in the analysis were summarized using simple pro-
portions for categorical variables and medians with inter-
quartile ranges (IQR) for continuous variables. We used a
multivariate Cox proportional hazards model to calculate an
adjusted association of gender with all-cause mortality. To
calculate the association of gender with change in CD4 count
from baseline to 12, 24, and 36 months, we used a multivariate
linear generalized estimating equation (GEE) model. In both
cases, we controlled for potential confounders, including age,
time on ART, year of ART initiation, current tuberculosis in-
fection, World Health Organization (WHO) stage, CD4 count,
body mass index (BMI), and hemoglobin count.
In both models, we used inverse probability of censoring
weights to adjust for selection bias due to loss to follow-up.27–29
Inverse probability of censoring weights reweight individuals
who do not become lost to represent those who become lost
and, thus, create a weighted pseudopopulation that repre-
sents the overall population had there been no censoring,
subject to the exchangeability assumption.28 Stabilized
weights were obtained by fitting two pooled logistic regres-
sion models for becoming lost, one controlling for baseline
predictors of loss to follow-up (gender along with baseline
same as the baseline covariates), and a second controlling
for baseline covariates as well as time-updated and time-
dependent predictors of becoming lost (current CD4 count,
BMI, and hemoglobin). although similarly constructed
weights (inverse probability of treatment weights) can be
used to adjust for confounding,27 we did not apply these
to this analysis, as treatment in this case is gender, which is
time-fixed at baseline, which means that controlling for time-
updated covariates in treatment weights may bias our esti-
mates, as these may be affected by gender and not vice versa.
To directly address the issue of whether any differences in
immunologic response by gender are actually a reflection of
differences in patterns of adherences, our primary analysis
was performed on those with a suppressed HIV viral load
(< 400 copies/mL) within the first 6 months after initiating
ART. We did this to determine the relationship between
gender and mortality and immunologic response among a
population of HIV-infected adults who we could reasonably
assume were at least initially adherent to treatment—in other
words, where the association between gender and the mea-
sured outcomes was not likely to be mediated through ad-
herence. We then also performed a mediation analysis where
we adjusted all models for updated viral load status (sup-
pressed or unsuppressed) to determine if the association of
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gender mediated through viral load (and, by proxy, adher-
ence) differed from those in the main analysis.
Results
Of the 11,692 patients eligible for analysis, 8,119 (69%) had
a viral load measurement at 6 months, and 7,354 (91%) of
those achieved viral suppression and were included in our
analysis. This included 63% (n = 4,621) women and 37%
(n = 2,733) men. The majority of patients were on d4T/3TC/
EFV (90.1%). Patients had a median CD4 count of 93 cells/
mm3 (IQR 36–159), a median age of 36.7 years (IQR 31.6–43.0),
and a median follow-up time on ART of 35.4 months (IQR
20.3–54.7) (Table 1). At ART initiation, men were older (me-
dian 37.9 vs. 35.8 years) and had more risk factors for poorer
treatment outcomes than women. Men sought treatment with
a lower median CD4 cell count (81 vs. 100 cells/mm3) and a
lower median BMI (20.4 vs. 22.5 kg/m2) and were more likely
to be classified with a WHO clinical stage III/IV condition
(46.3% vs. 40.5%) than women.
Mortality
By the end of the study follow-up, 333 (4.5%) patients had
died; 1,382 (18.8%) were lost to follow-up, and 598 (8.1%) had
transferred to another treatment facility. A higher proportion
of men than women (5.2% vs. 4.1%, p = 0.026) died during the
follow-up period. Similarly, a larger percentage of males were
lost than their female counterparts (21.1% vs. 17.4%, p < 0.001).
Although there was no difference in risk of death at 12 months
on treatment, adjusted hazard ratios (HR) showed men had a
20% higher risk of death at both 24 months (HR 1.2, 95%
confidence interval [CI] 0.9-1.6) and 36 months (HR 1.2, 95%
CI 0.9-1.6) of follow-up compared to women (Table 2). Both
these estimates, however, overlapped the null. Additionally,
older age and anemia were predictive of death at 12, 24, and
Table 1. Baseline Characteristics and Outcomes of ART Patients at Themba Lethu Clinic
Stratified by Gender (n = 7,354)
Gender
Characteristic Male (n = 2,733) Female (n = 4,621) Total (n = 7,354)
Age, years
18–24.9 49 (1.8%) 274 (5.9%) 323 (4.4%)
25–29.9 252 (9.2%) 747 (16.2%) 999 (13.6%)
30–39.9 1341 (49.1%) 2090 (45.2%) 3431 (46.7%)
40–49.9 780 (28.5%) 1129 (24.4%) 1909 (25.9%)
> 50 311 (11.4%) 381 (8.3%) 692 (9.4%)
CD4 at ART Initiation (cells/mm3)
0–50 987 (36.1%) 1330 (28.8%) 2317 (31.5%)
51–100 586 (21.4%) 950 (20.6%) 1536 (20.9%)
101–200 887 (32.5%) 1792 (38.8%) 2679 (36.4%)
201–350 228 (8.3%) 480 (10.4%) 708 (9.6%)
Missing 45 (1.7%) 69 (1.4%) 114 (1.6%)
WHO stage at ART initiation
I/II 1468 (53.7%) 2750 (59.5%) 4218 (57.4%)
III 1057 (38.7%) 1590 (34.4%) 2647 (36.0%)
IV 208 (7.6%) 281 (6.1%) 489 (6.6%)
First-line ART regimen
d4T/3TC/EFV 2484 (90.9%) 4143 (89.6%) 6627 (90.1%)
d4T/3TC/NVP 156 (5.7%) 363 (7.9%) 519 (7.0%)
AZT/3TC/EFV 87 (3.2%) 102 (2.2%) 189 (2.6%)
AZT/3TC/NVP 6 (0.2%) 13 (0.3%) 19 (0.3%)
CD4 at ART Initiation (cells/mm3)
Median (IQR) 81 (29–151) 100 (41–163) 93 (36–159)
Time on ART (months)
Median (IQR) 35.1 (19.5–53.9) 35.8 (21.0–55.2) 35.4 (20.3–54.7)
Hemoglobin at ART Initiation (lg/dL)
Median (IQR) 12.5 (10.7–14.0) 11.2 (9.8–12.5) 11.7 (10.1–13.0)
BMI at ART Initiation
Median (IQR) 20.4 (18.5–22.7) 22.5 (19.7–25.9) 21.6 (19.1–24.7)
Age at ART Initiation
Median (IQR) 37.9 (33.3–43.9) 35.8 (30.6–42.3) 36.7 (31.6–43.0)
Outcomes
Death, n (%) 143 (5.2) 190 (4.1) 333 (4.5)
Loss to follow-up, n (%) 576 (21.1) 806 (17.5) 1382 (18.8)
Transferred, n (%) 195 (7.1) 403 (8.7) 598 (8.1)
Alive and in care, n (%) 1819 (66.6) 3222 (69.7) 5041 (68.6)
ART, antiretroviral therapy; AZT, zidovudine; BMI, body mass index; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; NVP,
nevirapine; 3TC, lamivudine; WHO, World Health Organizations.
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36months of follow-up. Estimates were also adjusted for time
on ART, baseline WHO stage, baseline hemoglobin, baseline
BMI, tuberculosis status at ART initiation, and year initiated
onto ART.
Difference in CD4 count response
As expected, this population of initially virally suppressed
patients showed good immune responses to treatment. Wo-
men demonstrated better median CD4 count increases from
baseline than men across all time periods after ART initiation
(Fig. 1): an increase of 166 cells/mm3 (IQR 99–245) vs. 139
cells/mm3 (IQR 82–204) by 12-months, 277 cells/mm3 (IQR
183–384) vs. 218 cells/mm3 (IQR 148–309) by 24 months, and
343 cells/mm3 (IQR 240–481) vs. 272 cells/mm3 (IQR 184–
381) by 36 months on treatment. Estimates from adjusted
models also demonstrated disadvantages in immunologic
response for men at all time periods, and the differences, al-
though small in the first 12 months on ART, increased with
increasing time on treatment (Table 3). The mean differences
in CD4 count gains made by women and men between
baseline and 12, 24, and 36 months were 28.2 cells/mm3 (95%
CI 22.2–34.3), 60.8 cells/mm3 (95% CI 71.1-50.5 cells/mm3),
and 83.0 cells/mm3 (95% CI 97.1-68.8 cells/mm3), respec-
tively. Additionally, patients with lower CD4 cell count at
ART initiation and more advanced age ( > 40 vs. < 40 years)
demonstrated a poorer CD4 cell count increase from baseline
to 12, 24, and 36 months of follow-up.
Our results demonstrate similar findings to those from
previous studies despite accounting for selection bias due to
loss to follow-up. This, however, could be because loss to
follow-up is, in fact, a mixture of various outcomes, including
death,26 so the usefulness of CD4 count in predicting loss to
follow-up may be limited. In a sensitivity analysis, we in-
cluded a second set of weights to adjust for death. These
weights were constructed similarly to the censoring weights
and made no qualitative difference to our results.
Mediation analysis
We performed mediation analyses estimating the relation-
ships among gender and mortality and increase in CD4 cell
count mediated through adherence by adjusting models for
current HIV viral load status (suppressed to < 400 copies/mL
or not). The risk of death for men compared to women was
unchanged at 12 months on treatment (HR 1.0, 95% CI 0.9-1.6),
and men again had a 20% higher risk of death at both 24 (HR
1.2, 95% CI 0.9-1.6) and 36 months (HR 1.2, 95% CI 1.0-1.6) of
follow-up compared to women. The estimates of difference in
CD4 count increase also showed very similar results to the
primary analysis: men had disadvantages in immunologic re-
sponse for all time periods, and the differences again increased
with increasing time on treatment. The difference in CD4 count
gains made by women compared to men between baseline and
12 months was 28.2 cells/mm3 (95% CI 22.0-34.3) greater for
women. By 24 months, the difference was 60.8 cells/mm3 (95%
CI 71.1-50.5), and by 36 months, this had increased to 83.0
cells/mm3 (95% CI 97.1-68.8) favoring women.
We performed further analyses restricted to those with
suppressed viral loads at each time point considered. The
proportion missing viral load data was similar at the time
Table 2. Crude and Adjusted Hazard Ratios of Mortality (n = 7,020)














Gender Male vs. female 1.0 (0.7–1.5) 1.0 (0.7–1.5) 1.2 (0.9–1.6) 1.2 (0.9–1.6) 1.3 (1.0–1.6) 1.2 (0.9–1.6)
Age ‡ 40 vs. < 40 1.3 (0.9–1.9) 1.4 (1.0–2.0) 1.4 (1.1–1.8) 1.5 (1.1–1.9) 1.3 (1.0–1.7) 1.4 (1.1–1.8)
Baseline CD4
count (cells/mm3)
100–199 vs. 200–350 0.7 (0.4–1.4) 0.7 (0.4–1.2) 0.8 (0.5–1.3) 0.7 (0.4–1.1) 0.9 (0.5–1.4) 0.8 (0.5–1.3)
50–99 vs. 200–350 1.1 (0.6–2.0) 0.9 (0.5–1.7) 1.1 (0.7–1.8) 0.9 (0.5–1.5) 1.3 (0.8–2.1) 1.1 (0.6–1.8)
0–50 vs. 200–350 1.3 (0.7–2.4) 1.1 (0.6–2.0) 1.4 (0.9–2.2) 1.0 (0.6–1.7) 1.6 (1.0–2.5) 1.2 (0.8–2.0)
Baseline hemoglobin
(lg/dL)
< 10.0 vs. ‡ 10.0 1.6 (1.1–2.3) 1.5 (1.0–2.3) 1.6 (1.2–2.1) 1.5 (1.1–2.1) 1.6 (1.2–2.1) 1.5 (1.1–2.0)
Baseline BMI (kg/m2) < 17.5 vs. ‡ 17.5 1.3 (0.8–2.1) 1.1 (0.7–1.9) 1.4 (1.0–2.1) 1.2 (0.8–1.8) 1.5 (1.0–2.1) 1.2 (0.8–1.7)
aModels were also adjusted for time on ART, baseline WHO stage, baseline hemoglobin, baseline BMI, tuberculosis status at ART initiation,
and year initiated onto ART.
FIG. 1. Median increase in CD4 cell count at 12, 24, and 36
months of antiretroviral therapy (ART), stratified by gender
(n = 7,354).
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points considered (18% at 12 months, 17% at 24 months, and
17% at 36 months), and the proportion missing was similar for
women and men (17% vs. 18% at 12 months, 18% vs. 17% at 24
months, and 16% vs. 19% at 36 months). Results were almost
identical to the primary analysis for mortality. The estimates
of difference in CD4 count increase still demonstrated disad-
vantages for men for all time periods, although the differences
were somewhat smaller than those in the primary analysis.
The difference in CD4 count gains made by women compared
to men was 23.3 cells/mm3 (95% CI 18.5-28.2) greater for
women between baseline and 12 months, 35.5 cells/mm3
(95% CI 30.0-41.1) by 24 months, and 44.5 cells/mm3 (95% CI
35.5-53.9) by 36 months, favoring women.
Discussion
In this analysis of adults initiating treatment at a public
sector clinic in Johannesburg, South Africa, we demonstrate
gender differences in immunologic response to ART. Con-
trolling for baseline clinical factors (WHO stage and CD4
count) and age at ART initiation, we showed that women
demonstrated a small but consistently higher increase in CD4
cell count over 36 months of follow-up than men. Our results
are in agreement with previous studies of treatment outcomes
in the region, which have shown greater CD4 count increases
among women in addition to possible advantages for women
in terms of virologic outcomes.5,18,30,31
Gender disparate outcomes are of particular concern in
South Africa, which has the largest number of HIV-infected
adults in the world and an estimated 20% of all those receiving
ART globally.13 Estimates of gender differences in rates of
HIV progression and virologic and immunologic responses to
ART have varied.32,33 Early studies suggested that clinical
disease progression was more rapid in women than men.34–36
These differences were attributed to women being less likely
to initiate ART17 or receive treatment for opportunistic in-
fections, more likely to experience violence and discrimina-
tion, gynecologic morbidity,37 and pregnancy,38–40 and also
more likely to be anemic and younger at the time of ART
initiation.41 Conversely, more recent studies have shown that
women have a lower risk of morbidity and mortality42 and
better virologic and immunologic outcomes than men.5,18,30,43
Although the actual differences in immunologic response
to ART in our study were relatively small early after initiating
treatment, these differences tended to increase with increasing
time on treatment. This result alone may have important
public health implications because in sharp contrast to most
European and North American cohorts, proportionally more
women than men receive ART in Southern African co-
horts.41,44 In our own cohort, for example, > 60% of those
receiving ART were women. Thus, even modest differences in
absolute risk may have profound implications for a public
health approach to the administration of mass ART in South
and sub-Saharan Africa.
Previous studies have shown that baseline CD4 cell count
strongly predicts immunologic recovery.12 In our study, men
started treatment at lower median CD4 counts, which could
account for part of the persistent difference in CD4 gain
shown over time. We adjusted for baseline CD4 cell count in
all models in an attempt to account for these differences.
However, if disproportionately more men than women failed
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immunologic response. Previous studies that have shown
gender differences in clinical and immunologic outcomes
have postulated that that is owing to delayed presentation
and access to HIV care and also poor adherence once on
treatment, and women in this study presented at an earlier
disease stage than men. Findings were similar in both sub-
Saharan Africa5,41 and the United States,45 where women had
higher baseline CD4 counts and were less likely to have an
AIDS diagnosis at the time of starting ART. Studies from other
African countries suggest that women may seek medical help
earlier than men.44,46 If men seek care with more advanced
disease and with lower CD4 counts, they are likely to suffer
poorer outcomes, even after ART initiation.3,12 Financial
constraints have been cited as obstacles to accessing and re-
maining in care7–9,12,47,48; if this is the case, however, we
would expect to see fewer women accessing care, as they have
traditionally been overrepresented among the poorest groups
in society. In fact, Braitstein et al.41 showed that women in
resource limited settings were equally or more likely to access
HIV care and initiate ART than men. Somewhat paradoxi-
cally, employment may present more difficulties than finan-
cial constraints for those attempting to access treatment. As
more men (50.5%) were employed than women (40.1%) in this
cohort, problems getting time away from work for regular
clinic visits or loss of income due to days of work missed may
impact men more than women in a setting where clinic visits
often involve a significant part of the day spent in queues.
We also considered the effect of gender on mortality and
found no difference at 12 months on treatment, but point es-
timates suggested an increased hazard of death for men at 24
and 36 months on treatment; however, neither of these esti-
mates achieved statistical significance. This may be because of
the low event rate at these time points, and longer follow-up
may be required to determine if this represents a true effect.
Rates of ART adherence have been shown to differ by gen-
der.49,50 It is, therefore, reasonable to suspect that ART ad-
herence may mediate the relationship between gender and
ART outcomes. Our analysis attempted to control for adher-
ence by restricting the sample to those who achieved virologic
suppression. Although it has been shown that adherence and
virologic suppression are closely associated,51 there may be a
more subtle level of adherence that is not detected by a di-
chotomous virologic proxy variable. As we do not collect data
directly on patient adherence it is possible that residual con-
founding is present in the analysis. Despite this, results from
our mediation analysis were almost identical to those in the
primary analysis. This suggests that different patterns of ad-
herence do not fully explain the differences in CD4 gain by
gender and that other explanations should be considered.
Biologic differences between the genders, such as the influ-
ence of sex hormones on immunity,52 have been considered as
explanations, but recent work among female children demon-
strating lower viral loads and higher CD4 counts53 makes this
an unlikely explanation of all the effects seen. Differences in the
normal range of CD4 counts between men and women are also
possible explanations for differences in the rate of CD4 count
reconstitution demonstrated in this and other work. Previous
research has shown that women have higher CD4 counts than
their male counterparts among HIV-uninfected individuals as
well as for up to 5 years after HIV infection54,55 but that these
differences have little to no impact on rate of disease progres-
sion18 in the absence of ART. It is, thus, plausible that the ad-
vantages for women in terms of immunologic response are
related to the fact that women have a higher normal range to
return to after effective treatment is implemented.
Our findings should be considered in light of the limita-
tions of this study. As this is an observational study, we could
not fully rule out confounding bias due to systematic differ-
ences between the men and women in our study in terms of
health-seeking behavior (suggested by the greater proportion
of women accessing treatment and the earlier stage at which
women present) or other factors. However, we controlled for
important predictors of our main outcome, minimizing the
potential bias of our main results. Moreover, as gender cannot
be randomized, carefully conducted observational studies are
the only way to isolate gender-specific effects.
As with any study, results can be significantly biased by
high rates of loss to follow-up. This is of particular concern if
those who are lost to follow-up are significantly different from
those who remain in the study in terms of the exposure or
outcome of interest. The rates of loss to follow-up were 4-fold
higher among men than women in this cohort, and, thus, the
group of men who remained in care were likely to be at less
risk of poor treatment outcomes and death than the women
who remained in care. We used inverse probability of cen-
soring weights to correct for this effect; but if correction was
incomplete, residual bias from differential loss to follow-up
may remain. A related issue is that of missing data, of which
loss to follow-up is a special case. Here, we were missing viral
loads throughout follow-up period. If those viral loads were
associated with the true value of the missing viral loads (e.g.,
if unsuppressed viral loads were more likely to be missing
than suppressed viral loads), analysis of the effect of gender
on CD4 count or mortality might be biased. Sensitivity anal-
ysis among only those with suppressed viral load, however,
suggests that any such effect is likely to be small.
Conclusions
Despite the limitations, our results are valuable in under-
standing the role of gender in response to ART in a resource-
limited setting. We used several methodologic techniques in a
large cohort of HIV-infected individuals to add to the debate
about gender effects. We account for differences in adherence by
restricting analysis to initially virally suppressed individuals
and corrected for bias as a result of differing rates of loss to
follow-up, a problem that can plague cohort analyses. Cur-
rently, men are accessing this treatment program with lower
CD4 counts and at a later stage in disease progression compared
to women. To improve this situation, it is important that
counseling and testing programs target men in their publicity
campaigns. The establishment of male-friendly clinic practices
may facilitate earlier counseling and testing as well as access to
treatment among men. This could include after-hours access,
weekend clinics, workplace facilities for HIV counseling and
testing, and alternative locations for obtaining treatment, such
as post office medication collection points. Consideration of
interventions such as these may begin to address gender dif-
ferences due to late presentation. Once access to care is equal, the
true biologic differences between genders may become clearer.
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